Kyntra Bio halts FG-3246 prostate cancer trial, narrows focus to roxadustat
The company stopped its FG-3246/FG-3180 program after a Phase 2 interim look, restructured its royalty debt, and tied its Phase 3 roxadustat trial start to new financing or a partner.
Kyntra Bio said on November 16, 2026 that it is discontinuing development of FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer. After reviewing a pre-specified interim analysis of the ongoing Phase 2 study of FG-3246 in mCRPC, the company closed enrollment and ended the program because preliminary efficacy results did not clear the bar set for continuing the trial.1 Kyntra Bio plans to wind down the study over the coming months and expects the move to cut operating expenses by more than $20 million across 2027 and 2028.1
The company is now positioning itself as a rare-disease specialist built around roxadustat for anemia in lower-risk myelodysplastic syndrome (LR-MDS) patients with high transfusion burden. CEO Thane Wettig said the FG-3246 trial was terminated following the interim analysis, and the company is working to complete its shift to a pure-play rare disease business centered on the roxadustat Phase 3 program.1 Wettig said the pivotal Phase 3 trial start, targeted for the first quarter of 2027, depends on either lining up a strategic partner or raising outside capital.1
On the balance sheet side, Kyntra Bio said in August 2026 it amended and restated its royalty financing agreement with NQ Project Phoebus, L.P., cutting its maximum payment obligation from $125 million to $65 million in exchange for an accelerated upfront payment of $42.6 million, bringing total payments to NQ Project Phoebus to $50 million and fully returning that firm's invested capital.1 Remaining payments are capped at $15 million and will come from half of the roxadustat drug product revenue Kyntra Bio books from Astellas outside Japan; once that cap is hit, the agreement ends and Kyntra Bio keeps all future EVRENZO royalties in those territories.1
As of September 30, 2026, Kyntra Bio held $44.1 million in cash, cash equivalents, investments and accounts receivable, which the company said should fund its operating plans into 2028.1 The company also appointed Andrew E. Singer, MBA, to its board of directors.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.